The California Department of Health has issued an All Facilities Letter regarding the ongoing investigation of contamination at the New England Compounding Center's (NECC) facility. The sterility of any injectable drugs, ophthalmic drugs, and cardioplegic solutions produced by NECC is of significant concern. Healthcare providers are recommended to contact patients who received these products and instruct them to seek immediate medical attention if they experience any symptoms. This is a result of a multistate fungal and bacterial meningitis outbreak associated with recalled lots of compounded methylprednisolone acetate. The letter advises facilities to follow up with patients who meet specific criteria, including receiving injectable products from NECC on or after May 21, 2012. This is an ongoing investigation, and information is subject to change daily. Healthcare facilities should visit the CDC or FDA MedWatch websites for the most up-to-date information on this outbreak.

Summaries are generataed using AI. Check important information.